Source-backed biotech intelligence, linked from evidence to output.
Source Ledger Bio helps research teams connect SEC filings, ClinicalTrials.gov records, FDA resources, official company pages, pipeline assets, trials, rights, and uncertainty in one traceable workspace.
Early signups receive launch updates, launch timing, and early bird specials when pricing becomes available.
Evidence-linked biotech view
Built to show source coverage, accepted links, candidate signals, and unresolved gaps without pretending missing coverage is zero.
Complete, blocked, or needs review
Linked to stored source context
No fake zeros or hidden assumptions
Sponsor-only and collaborator-only trial signals remain candidate evidence until the source chain supports a governed relationship.
Core outputs
Built for how biotech diligence actually works.
The public beta is focused on source-backed company, asset, trial, regulatory, financial, and rights context. Unsupported market-provider widgets stay out of the primary product story.
Company Snapshot
Identity, filings, coverage health, and what remains unresolved.
Governed Pipeline
Company-backed assets separated from candidate and regulatory-only signals.
Trial View
Trial records connected through asset identity, not sponsor-only shortcuts.
Evidence Panel
Source snapshots, extracted claims, confidence, and caveats in one place.
What Changed
A focused feed of source updates, blockers, and uncertainty that matter.
The problem
Biotech research is fragmented before the real analysis even starts.
Teams spend hours moving between filings, registries, official pages, regulatory records, and press releases before they can answer basic relationship questions.
SEC filings and SEC CompanyFacts live separately from company pipeline pages.
ClinicalTrials.gov records rarely explain whether a trial proves company ownership.
FDA applicant, labeler, sponsor, collaborator, and rights-holder roles are easy to confuse.
Press releases, investor pages, and deal disclosures change the story over time.
Manual research makes it hard to know what is source-backed, stale, missing, or uncertain.
How it helps
One source-backed workspace for what is known, what matters, and what remains uncertain.
Source Ledger Bio is designed to bring the evidence, linking logic, and output views into the same research flow, so users can move from source documents to governed conclusions without losing provenance.
Company snapshots
Identity, filings, official sources, source coverage, and unresolved blockers.
Governed pipeline
Company-backed assets, candidate assets, regulatory products, and evidence state.
Trial view
Trial records and bridges that distinguish study status from development-stage claims.
Evidence panel
Stored snapshots, extracted claims, confidence, source URLs, and what each claim does not prove.
Truth-first method
A structured evidence flow, not random AI output.
The product model is intentionally explicit: raw sources become snapshots, snapshots become evidence claims, claims resolve into identities and links, and governance determines what users can trust.
Raw Sources
SEC EDGAR, SEC CompanyFacts, ClinicalTrials.gov, FDA resources, Drugs@FDA, official company pages, press releases, and deal disclosures.
Identity & Evidence
Source snapshots and evidence claims capture what the source actually says, when it was found, and how reliable it is.
Linking Logic
Companies, assets, trials, products, and deals are linked through explicit rules, aliases, and source-backed relationships.
Governance
Weak, candidate, stale, conflicted, and accepted evidence stay separate so conclusions do not outrun the source chain.
User Outputs
Research-ready company views show what is known, what matters, and what is still uncertain.
Features and benefits
Designed to reduce manual source-hopping without hiding uncertainty.
The private beta is centered on research workflows that can be traced back to public and official sources.
Source-backed company research
Company identity, filings, official sources, and source coverage stay visible instead of disappearing behind generic summaries.
Trial and asset intelligence
Trial records, interventions, aliases, and company-backed asset signals are connected with clear evidence state.
Evidence-linked views
Outputs are designed to trace back to stored snapshots, extracted claims, original source links, and governance decisions.
Company/program relationships
The platform separates owned, licensed, partnered, sponsor-only, FDA-applicant, and candidate-only signals.
Uncertainty made visible
Missing URLs, stale sources, blocked fetches, weak links, and review needs are shown as research state, not hidden.
One place for the diligence map
SEC, trial, FDA, official company, and deal evidence can be reviewed together instead of rebuilt manually.
Who it is for
For teams that need evidence-aware biotech diligence.
Source Ledger Bio is for people who need a credible research map before they make their own decisions.
Biotech investors
Research public-company programs, catalysts, cash context, and unresolved source gaps.
Analysts
Build a source-backed view of companies, assets, trials, and evidence without starting from scratch.
Due diligence teams
Trace relationship claims and separate accepted evidence from candidate signals.
Family offices and small funds
Track fragile biotech stories with better provenance and less manual source hopping.
Biotech operators
Understand how external evidence presents company programs, assets, and uncertainty.
Specialized researchers
Use one structured workspace for filings, registries, products, rights, and review tasks.
Coming soon
Create an account for launch updates and early access news.
Source Ledger Bio is not selling paid plans yet, and pricing is not public yet. Early signups will receive launch updates, early bird specials, launch timing, and pricing updates when they are available.
Only approved private beta accounts can reach the download area.
The beta focuses on source-backed biotech research, not unsupported market widgets.
Source Ledger Bio organizes evidence. It does not provide medical, legal, or investment advice.